iLIVER最新文献

{"title":"A retrospective cohort study to examine the association between the persistence of abdominal pain after cholecystectomy and ejection fraction on HIDA scan in patients with biliary dyskinesia","authors":"Baldeep Kaur Mann ,&nbsp;Janpreet Singh Bhandohal ,&nbsp;Ishaan Kalha ,&nbsp;Brian Jean","doi":"10.1016/j.iliver.2023.10.003","DOIUrl":"10.1016/j.iliver.2023.10.003","url":null,"abstract":"<div><h3>Background and aims</h3><p>The persistence of pain in patients who underwent cholecystectomy primarily for biliary dyskinesia has been associated with gall bladder ejection fraction (GBEF) found on hepatobiliary iminodiacetic acid (HIDA) scan. Cholecystectomy is a definitive treatment for cholelithiasis but is questionable in biliary dyskinesia. During the postoperative follow-up, gastroenterologists and surgeons often found that some patients with biliary dyskinesia continue to experience biliary pain even after surgery. This study aims to investigate whether the value of GBEF found on the HIDA scan predicts the persistence of pain after cholecystectomy in patients with biliary dyskinesia (EF &lt;35% on HIDA scan).</p></div><div><h3>Methods</h3><p>It is a retrospective cohort study conducted at Kern Medical by recruiting patients from November 2019 to October 2022 in consecutive manner. It is a single sample study consisting of post-cholecystectomy biliary dyskinesia patients with dichotomous outcomes, i.e., persistent typical recurrent epigastric or right upper quadrant pain with/without meals versus no pain. The primary outcome was the presence of pain 30 days after the cholecystectomy. Univariate analysis was performed with some of the bivariate indicators and continuous predictors, which contained fewer missing elements and had more variation.</p></div><div><h3>Results</h3><p>Univariate logistic regression suggested that HIDA GBEF as a continuous variable does not suggest a relationship with pain after surgery (<em>p</em> = 0.3951). A ROC analysis suggested a cutoff of HIDA GBEF = 16 (AUC = 0.60, Specificity = 0.5455, Sensitivity = 0.7333).</p></div><div><h3>Conclusion</h3><p>Our study does not support the relationship between GBEF found on HIDA scan to improved outcomes after the surgery. But larger controlled trials comparing outcomes of the patients with biliary dyskinesia who did and didn't undergo cholecystectomy are needed to look for other factors.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"2 4","pages":"Pages 208-213"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947823000488/pdfft?md5=933a22542fb9be778c1c930efc43e5eb&pid=1-s2.0-S2772947823000488-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136128016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intrahepatic cholestasis of pregnancy is associated with increased risk of hepatobiliary disease and adverse fetal outcomes: A systematic review and meta-analysis","authors":"Peter Olujimi Odutola ,&nbsp;Peter Oluwatobi Olorunyomi ,&nbsp;Olanrewaju Olamide Olatawura ,&nbsp;Ifeoluwapo Olorunyomi ,&nbsp;Olukayode Madojutimi ,&nbsp;Ayomide O. Fatunsin ,&nbsp;Uju Okeke","doi":"10.1016/j.iliver.2023.11.001","DOIUrl":"10.1016/j.iliver.2023.11.001","url":null,"abstract":"<div><h3>Background and aims</h3><p>The aim of this study was to review the literature and perform a meta-analysis to clarify the association between intrahepatic cholestasis of pregnancy and risks of long-term maternal hepatobiliary disease as well as adverse fetal outcomes including preterm birth, meconium-stained amniotic fluid, and stillbirth.</p></div><div><h3>Methods</h3><p>This systematic review and meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A comprehensive literature search was performed using Cochrane, Embase, and PubMed databases to identify observational or cohort studies comparing pregnant women with intrahepatic cholestasis of pregnancy (ICP) to pregnant women without ICP. Data from the included studies were analyzed using the Review Manager 5.4.1 software.</p></div><div><h3>Results</h3><p>The meta-analysis showed a significant association between ICP and the risk of hepatobiliary diseases (pooled risk ratio [RR]: 2.81, 95% confidence interval [CI]: 2.66–2.97, <em>p</em> &lt; 0.00001), hepatitis C (HC): a significant association between ICP and risk of HC (pooled RR: 4.02, 95% CI: 3.12–5.19, <em>p</em> &lt; 0.00001), meconium-stained amniotic fluid (MSAF): ICP was significantly associated with an increased risk of MSAF (pooled RR: 1.91, 95% CI: 1.65–2.21, <em>p</em> &lt; 0.00001), and preterm birth: the meta-analysis demonstrated a significant association between ICP and preterm birth (pooled RR: 2.11, 95% CI: 2.01–2.21, <em>p</em> &lt; 0.00001).</p></div><div><h3>Conclusion</h3><p>ICP demonstrated statistically significant associations with increased risks of hepatobiliary disease, HC, MSAF, and preterm birth.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"2 4","pages":"Pages 219-226"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S277294782300049X/pdfft?md5=d36b2c294671ab21de9c42465cca01cc&pid=1-s2.0-S277294782300049X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135714993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of positive cofactor 4 as a diagnostic and prognostic biomarker associated with immune infiltration in hepatocellular carcinoma","authors":"Liangliang Bai ,&nbsp;Guan Liu ,&nbsp;Gang Dou ,&nbsp;Xiaojun He ,&nbsp;Chenyu Gong ,&nbsp;Hongbin Zhang ,&nbsp;Kai Tan ,&nbsp;Xilin Du","doi":"10.1016/j.iliver.2023.08.007","DOIUrl":"10.1016/j.iliver.2023.08.007","url":null,"abstract":"<div><h3>Background and aims</h3><p>Human positive cofactor 4 (PC4) is associated with the development and therapeutic resistance of several malignancies. However, the role of PC4 in hepatocellular carcinoma (HCC) remains obscure.</p></div><div><h3>Methods</h3><p>The expression status of PC4 was explored in Gene Expression Omnibus and The Cancer Genome Atlas datasets. Subsequently, the prognostic and diagnostic significance of PC4 in HCC patients was analyzed. Functional enrichment analyses were conducted to explore biological functions and potential mechanisms. The CIBERSORT algorithm was used for immune infiltration analysis. The risk signature was constructed by LASSO-Cox regression and was validated with the International Cancer Genome Consortium dataset. Quantitative real-time polymerase chain reaction was used to verify the expression levels of all genes. Tumor Immune Dysfunction and Exclusion analysis evaluated immunotherapy response. Finally, using online databases, PC4-related competing endogenous RNA networks were constructed.</p></div><div><h3>Results</h3><p>PC4 levels were significantly upregulated in HCC and positively correlated with the pathological grade and clinical stage. The PC4-high expression group showed worse prognosis. In addition, PC4 could distinguish between tumor and normal tissues with an area under the curve of 0.965. The PC4 level was associated with immune checkpoints and immune cell infiltration. In the training and validation sets, the eight-gene risk signature strongly correlated with HCC patient prognosis. Tumor Immune Dysfunction and Exclusion analysis showed that patients in both the PC4-low and low-risk groups were more likely to benefit from immunotherapy. Finally, an lncRNA/microRNA-101-3p/PC4 network was constructed.</p></div><div><h3>Conclusion</h3><p>We confirmed PC4 as a diagnostic and prognostic biomarker in HCC patients. We also developed and validated an eight-gene risk signature, which will help in clinical decision-making. The competing endogenous RNA network could help explore the regulatory mechanisms of PC4 in HCC.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"2 4","pages":"Pages 188-201"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947823000385/pdfft?md5=930d9cb49c9e240b356b591e6696644d&pid=1-s2.0-S2772947823000385-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135346669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Laparoscopic cholecystectomy based on Laennec approach via the cystic plate with lymphadenectomy in Calot's triangle for gallbladder neoplasms: Initial experience and technical details","authors":"Bin Ouyang ,&nbsp;Laizhu Zhang ,&nbsp;Yajuan Cao ,&nbsp;Zhongjie Xing ,&nbsp;Jin Peng ,&nbsp;Yang Yue ,&nbsp;Decai Yu","doi":"10.1016/j.iliver.2023.10.001","DOIUrl":"10.1016/j.iliver.2023.10.001","url":null,"abstract":"<div><h3>Background</h3><p>It is still challenging to define the exact stage of early gallbladder carcinoma with preoperative imaging. Generally, subserous gallbladder is dissected for the potential early gallbladder carcinoma, which may cause incomplete tumor resection or tumor spread especially for the patients with T2 stage. Here, we reported our experience and safety of Laennec approach via the cystic plate to dissect the whole gallbladder with lymphadenectomy in Calot's triangle for accurate diagnosis and stage in gallbladder neoplasms.</p></div><div><h3>Methods</h3><p>The anatomical gap between Laennec capsule and the cystic plate serves as the landmark to dissect the whole gallbladder through Laennec approach. Laparoscopic cholecystectomy based on Laennec approach via the cystic plate, together with lymphadenectomy in Calot's triangle, was performed in 17 patients with gallbladder neoplasms.</p></div><div><h3>Results</h3><p>All patients had less intraoperative bleeding, no gallbladder breakage, no bile leakage, and accurate intraoperative rapid pathological staging under the corresponding strategies. The duration of surgery was comparable to that of traditional laparoscopic cholecystectomy.</p></div><div><h3>Conclusion</h3><p>Laparoscopic cholecystectomy based on Laennec approach via the cystic plate, together with lymphadenectomy in Calot's triangular is safe for gallbladder neoplasms. In the future, the prospective clinical trial is going on to confirm the feasibility and effectiveness of this approach.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"2 4","pages":"Pages 202-207"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947823000464/pdfft?md5=0e69e827749a60ba27f7bfdbc17e8206&pid=1-s2.0-S2772947823000464-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135810975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Publication characteristics and visualized analysis of research about liver sinusoidal endothelial cells","authors":"Shanshan Zhao ,&nbsp;Lan Zhang ,&nbsp;Junzhe Zhao ,&nbsp;Farah Tasnim ,&nbsp;Hanry Yu","doi":"10.1016/j.iliver.2023.11.002","DOIUrl":"https://doi.org/10.1016/j.iliver.2023.11.002","url":null,"abstract":"<div><h3>Background and aims</h3><p>Through visual analysis of related literature, the main research direction and hot spots of liver sinusoidal endothelial cells (LSECs) in recent 24 years were explored.</p></div><div><h3>Methods</h3><p>This study used bibliometric analysis with CiteSpace, VOSviewer, Biblioshiny and online analytic tool <span>bibliometric.com</span><svg><path></path></svg> to provide a quantitative analysis, hot spot mining, and commentary of articles published in the field of LSECs research. The relevant literature in the Web of Science Core Collection (WOSCC) was searched from 2000 to 2023. The publications with topics or titles or keywords containing LSECs were included into this study. The countries, organizations, journals, authors, and keywords of the publications were summarized and analyzed.</p></div><div><h3>Results</h3><p>This study included 3,747 publications from 14,132 authors belonging to 389 institutions in 61 countries/regions and published in 150 journals, with 156,309 citations. The United States contributed most (1,150) to the publications. The most productive institution was the University of Sydney. <em>Hepatology</em> accounts for the most output (293, 7.8​%), European authors had a widespread cooperation. The most productive author was Adam DH with 68 papers. Immunological function of LSECs is research hot spot.</p></div><div><h3>Conclusion</h3><p>This study highlights key trends based on a large dataset of the most influential publications about LSECs research over a 24-year period. It provides important clues and ideas for researchers focusing in this area and facilitates future liver disease mechanism, understanding, and treatment.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 1","pages":"Article 100075"},"PeriodicalIF":0.0,"publicationDate":"2023-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947823000506/pdfft?md5=ecdacfaa6950185d24d1155ccad17e0a&pid=1-s2.0-S2772947823000506-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139693900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Volatile organic compounds for the detection of hepatocellular carcinoma—A scoping review","authors":"Sayed Metwaly ,&nbsp;Alicja Psica ,&nbsp;Opeyemi Sogaolu ,&nbsp;Irfan Ahmed ,&nbsp;Ashis Mukhopadhya ,&nbsp;Mirela Delibegović ,&nbsp;Mohamed Bekheit","doi":"10.1016/j.iliver.2023.09.001","DOIUrl":"10.1016/j.iliver.2023.09.001","url":null,"abstract":"<div><p>Hepatocellular carcinoma (HCC) is an increasingly common and the second leading cause of cancer mortality worldwide with a 5-year survival rate about 12%. Less than 20% of HCC patients are eligible to curative treatment owing to the late presentation. Clearly, there is a need for a readily accessible, early screening tool. This scoping review critically appraises and synthesizes the current published knowledge about the use of exhaled volatile organic compounds (VOCs) as a potential noninvasive means for HCC detection aiming to advance this nascent field. A systematic electronic search was conducted. The search strategy included all studies published until the 24th of March 2023 using a combination of relevant keywords. The search yielded 9 publications using the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Two of the studies described in vitro experiments, and seven clinical studies were conducted on small groups of patients. Overall, 42 headspace gases were analyzed in the in vitro studies. Combined, the clinical studies included 420 HCC patients and 630 controls. The studies reported potential role for a combination of VOCs in the diagnosis of HCC. However, there is lack of consensus. Although there appears to be promise in VOCs research associated with HCC, there is no single volatile biomarker in exhaled breath attributed to HCC and data from extracted studies indicates a lack of standardization. Large multicentre population studies are required to verify the existence of VOCs linked to HCC.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"3 1","pages":"Article 100070"},"PeriodicalIF":0.0,"publicationDate":"2023-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772947823000452/pdfft?md5=cd14d50b37f5452cfcfbeb72231a1ecc&pid=1-s2.0-S2772947823000452-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135607246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HCC case management-related challenges: Think outside the box!","authors":"Nourhan Badwei","doi":"10.1016/j.iliver.2023.08.001","DOIUrl":"https://doi.org/10.1016/j.iliver.2023.08.001","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"2 3","pages":"Pages 143-145"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49717349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prednisolone therapy accelerates recovery of severe drug-induced liver injury: A prospective, randomized controlled study","authors":"Fang-Jiao Song ,&nbsp;Hong-Ling Liu ,&nbsp;Ying Sun ,&nbsp;Tian-Jiao Xu ,&nbsp;Dong-Ze Li ,&nbsp;Hai-Bo Wang ,&nbsp;Shao-Jie Xin ,&nbsp;Yu-Dong Wang ,&nbsp;Gregory Cheng ,&nbsp;George Lau ,&nbsp;Sa Lv ,&nbsp;Shao-Li You ,&nbsp;Bing Zhu","doi":"10.1016/j.iliver.2023.06.001","DOIUrl":"https://doi.org/10.1016/j.iliver.2023.06.001","url":null,"abstract":"<div><h3>Background and aims</h3><p>Drug-induced liver injury (DILI) is one of the most serious adverse drug reactions and its incidence has been increasing rapidly. Accumulating evidence suggests that immune activation and systemic inflammatory responses are very important in the progression of DILI. Corticosteroids are often used in DILI, but their clinical usefulness remains controversial. We therefore conducted a prospective, randomized controlled study to investigate whether corticosteroid therapy can accelerate recovery and reduce mortality in severe DILI (SDILI).</p></div><div><h3>Methods</h3><p>SDILI patients with total bilirubin ≥171 μmol/L who presented to the Fifth Medical Center of Chinese PLA General Hospital, Beijing from 2016 to 2019 were randomly allocated to prednisolone and control groups. The endpoints were resolution of SDILI, defined as a decrease in total bilirubin of at least 35 μmol/L to &lt;171 μmol/L, and overall survival at 6 months. Patients in the prednisolone group received prednisolone 60 mg/day therapy for the first 7 days. Patients with a decrease in total bilirubin of more than 35 μmol/L on day 8 continued on tapering doses of prednisolone; otherwise, prednisolone was discontinued.</p></div><div><h3>Results</h3><p>On day 8, 50.75% (34/67) and 26.47% (18/68) of the participants in the prednisolone and control groups, respectively, achieved the primary endpoint (<em>p</em> = 0.002). However, there was no significant difference in overall survival at 6 months: 95.52% (64/67) vs. 91.18% (62/68) in the prednisolone and control groups, respectively (<em>p</em> = 0.3). All deaths in both groups occurred in patients who failed to achieve SDILI resolution on day 8.</p></div><div><h3>Conclusion</h3><p>Prednisolone therapy may accelerate the recovery of SDILI.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"2 3","pages":"Pages 156-162"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49735360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating Tislelizumab, Lenvatinib, and FOLFOX4-HAIC as a Conversion Therapy for Unresectable Hepatocellular Carcinoma","authors":"Kai Tan ,&nbsp;Xiaojun He ,&nbsp;Haoran Yuan ,&nbsp;Shoujie Zhao ,&nbsp;Chenyu Gong ,&nbsp;Yaoyao Zhao ,&nbsp;Haiyan Nan ,&nbsp;Li Zang ,&nbsp;Zhonghua Luo ,&nbsp;Xilin Du","doi":"10.1016/j.iliver.2023.08.003","DOIUrl":"https://doi.org/10.1016/j.iliver.2023.08.003","url":null,"abstract":"<div><h3>Background and aims</h3><p>Conversion therapy downstages tumors and renders patients with unresectable hepatocellular carcinoma (HCC) eligible for radical resection. This study aimed to evaluate the efficacy and safety of tislelizumab plus lenvatinib and hepatic artery infusion chemotherapy with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4-HAIC) as a first-line conversion therapy.</p></div><div><h3>Methods</h3><p>Clinical data from HCC patients who were treated with the triple therapy between April 2021 and April 2022 were retrospectively analyzed. The primary outcome included objective response rate (ORR), disease control rate (DCR), conversion resection rate (CRR), and treatment-related adverse events (TRAEs).</p></div><div><h3>Results</h3><p>A total of 18 patients completed conversion therapy assessment, which ended on March 27, 2023. The patients had a median age of 55.5 (37–72) years, and 94.4% were male. According to mRECIST, tumor shrinkage was observed in all patients, with an ORR of 94.4% (17/18), a DCR of 94.4% (17/18), and a median time to response of 1.4 (0.7–3.0) months. Successful conversion was observed in 61.1% (11/18) of patients (mRECIST). The CRR and pathological complete response were 38.9% (7/18) and 57.1% (4/7), respectively. The median progression-free survival (PFS) was 17.8 months, while median overall survival was not reached. The 6- and 9-month PFS rates were 83.3% and 66.7%, respectively. The most common TRAE (16/18 patients, 88.9%) was an increase in aspartate aminotransferase levels.</p></div><div><h3>Conclusion</h3><p>Tislelizumab combined with lenvatinib and FOLFOX4-HAIC achieved a high conversion rate and acceptable toxicity in patients with unresectable HCC, suggesting that this combination may represent a new conversion strategy for this population.</p></div>","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"2 3","pages":"Pages 163-169"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49717277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radio-granular hydrogels for image-guided tumor brachytherapy","authors":"Shilong Shao ,&nbsp;Xiao Xu ,&nbsp;Gan Lin ,&nbsp;Gang Liu","doi":"10.1016/j.iliver.2023.08.006","DOIUrl":"https://doi.org/10.1016/j.iliver.2023.08.006","url":null,"abstract":"","PeriodicalId":100657,"journal":{"name":"iLIVER","volume":"2 3","pages":"Pages 177-179"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49716958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}